The Middle East and Africa Liquid Biopsy Market size is expected to grow at a CAGR of 21.71% during the forecast period. As a result, the market size is predicted to value USD 421.95 million by 2027 from USD 157.99 million in 2022.
A liquid biopsy helps collect a wide range of information about cancer/tumors through a simple blood sample. For example, the procedure can help detect mutations in epidermal growth factor receptors in cancers. Liquid biopsies are also helpful in residual cancer detection, which can be performed with 5 milliliters of blood that would detect the present state of metastases in various tumors.
Liquid biopsy is a minimally invasive technique to analyze the non – solid biological tissues, mostly for the early detection of cancer. According to WHO, the number of cancer patients in the Middle East is increasing every year; according to WHO, the number will be double by 2030. Over 70% of deaths in the Middle East are due to cancer. According to WHO, 9 out of 22 countries in the Middle East do not have operational facilities for cancer treatment. Thus, the demand for liquid biopsy is increasing in this region as a liquid biopsy can be used to detect cancer. In addition, the liquid biopsy is less painful in comparison to traditional tissue biopsy. The government in this region is giving funds for the development of liquid biopsy to improve the health care service in this region. Inivata, a leading company in liquid biopsy, has signed a distribution agreement with IPS Genomix to provide InVisionFirst and InVisionSeq liquid biopsy tests in the Middle East and Africa.
Growing prevalence to improve healthcare infrastructures across the region is mainly propelling the demand of the market. The rise in the incidences of life-threatening diseases is also elevating the demand of the market. In addition, the rising number of cancer patients in the world coupled with innovation in liquid biopsy technology is anticipated to drive the global liquid biopsy market over the forecast period.
However, expensive medical procedures & a cost-intensive research process involved in the liquid biopsy are anticipated to restrain the development of the global liquid biopsy market over the next few years. In addition, the liquid biopsy required a skilled workforce, which is difficult to get. Lack of proper awareness over the availability of different treatment procedures is hindering the growth of the market. Unfavorable government policies are also impeding the demand of the MEA in-vitro diagnostics market.
This research report on the North American Liquid Biopsy Market has been segmented and sub-segmented market into the following categories:
By Cancer Type:
By Diagnostic Approach:
Regionally, UAE has the highest market share in the Middle East. The government is investing in the research and development of innovative products that solely fuel the market demand. Many institutes in this region are researching the liquid biopsy technique. The emergence of the latest techniques and promoting quality services in healthcare are enhancing the market's demand.
KEY MARKET PLAYERS:
A few of the promising companies operating in the MEA Liquid Biopsy Market are Janssen Diagnostics, Qiagen, Rarecells SAS, Silicon Biosystems, SRI International, Myriad Genetics, Natera, Personal Genome Diagnostics, Sysmex Inostics, Trovagene, Exosome Diagnostics, Exosome Sciences, and HansaBiomed OU.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org